Not a healthcare professional? Visit our Public site

report_adverse_events REPORT ADVERSE EVENT Login Register notification bell

Placeholder

    Contact us REQUEST A REPRESENTATIVE

    Your browser is not supported.

    To view this content, please use one of the following browsers:

    • Microsoft Edge
    • Chrome
    • Safari
    Rezzayo Logo

    Click here to access GB prescribing information or NI prescribing Information

    RESOURCES

    Expert presentations and opinions on REZZAYO® rezafungin

     

    Watch or listen to expert presentations and opinions on REZZAYO®, and access dedicated learning resources or materials for your patients

    Interested in learning more about how REZZAYO® could help in your hospital?
    Request an appointment with a Napp representative

    Request an appointment
    placeholder

    Mechanism of action (MOA)

    Discover the benefits of REZZAYO® mechanism of action

    VIDEO

     

    REZZAYO® rezafungin budget impact summary

    REZZAYO® rezafungin budget impact summary

    Calculate any potential cost saving that could be achieved by switching your patients from their current treatment.

    CALCULATOR

    REZZAYO® rezafungin budget impact summary

    REZZAYO® rezafungin Formulary Pack

    This formulary pack contains key data for how REZZAYO® rezafungin, as the first once-weekly echinocandin, can potentially support the treatment of invasive candidiasis 

    PDF

    Understanding invasive candidiasis Information guide for patients or carers of patients, receiving rezafungin

    Understanding invasive candidiasis

    Information guide for patients or carers of patients, receiving rezafungin to be given by UK Healthcare professional

    DOWNLOAD

    placeholder

    Introducing ▼REZZAYO® (rezafungin) the first once weekly echinocandin indicated for the treatment of invasive candidiasis in adults.

    Webinar introducing ▼REZZAYO® (rezafungin)

    VIDEO

     

    REZZAYO® rezafungin budget impact summary

    What's the importance of early fungal eradication in invasive candidiasis/ candidaemia?

    Professor Mikulska discusses the importance of early fungal eradication in invasive candidiasis/candidaemia.

    VIDEO

    UK-RZF-2400043 talking heads video

    What are the potential benefits of once-weekly REZZAYO® rezafungin in the ward?

    Professor Mikulska discusses the potential benefits of once-weekly REZZAYO® rezafungin in the ward?

    VIDEO

    UK-RZF-2400039 talking head video

    What's the importance of early fungal eradication in invasive candidiasis/ candidaemia?

    Professor Cornely the potential benefits of once-weekly REZZAYO® rezafungin in the ward.

    VIDEO

    UK-RZF-2400044 talking head video

    What are the challenges of managing DDIs with existing antifungals?

    Professor Cornely discusses what the challenges are of managing DDIs with existing antifungals.

    VIDEO

     

    UK-RZF-2400042 - talking head videos

    What are the potential benefits of once-weekly REZZAYO® rezafungin for discharge?

    Professor Mikulska discusses the potential benefits of once-weekly REZZAYO® rezafungin.

    VIDEO

    UK-RZF-2400056 - talking head videos

    Which drugs does REZZAYO® rezafungin interact with?

    Professor Cornely discusses which drugs interact with once-weekly REZZAYO® rezafungin.

    VIDEO

    Rezafungin patient appointment card

    Rezafungin patient appointment card

    Download the REZZAYO® rezafungin patient appointment card

    DOWNLOAD

    REZZAYO Clinical trial summary: ReSTORE

    REZZAYO® rezafungin ReSTORE clinical trial summary

    Key learnings from the ReSTORE trial

    DOWNLOAD

    REZZAYO® Pooled clinical trial summary

    REZZAYO® rezafungin Pooled clinical trial summary

    Key learnings from the Pooled clinical trial

    DOWNLOAD

    REZZAYO® Pooled clinical trial summary

    Implementation of REZZAYO® Through Formulary Submission - Webinar

    Watch as Consultant Antimicrobial Pharmacist Stephen Hughes talks about REZZAYO® and his experience with submitting for formulary at the Chelsea & Westminster NHS Trust.

    VIDEO

      Reporting adverse events

      Adverse events should be reported. Reporting forms and information can be found at http://yellowcard.mhra.gov.uk/.

      Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyUKandROI@mundipharma.com.

      ®: REZZAYO is a Registered Trademark of Napp Pharmaceutical Group Limited.